SV2003000600A - Combinacion terapeutica ref. pc11025aado/bb - Google Patents
Combinacion terapeutica ref. pc11025aado/bbInfo
- Publication number
- SV2003000600A SV2003000600A SV2001000600A SV2001000600A SV2003000600A SV 2003000600 A SV2003000600 A SV 2003000600A SV 2001000600 A SV2001000600 A SV 2001000600A SV 2001000600 A SV2001000600 A SV 2001000600A SV 2003000600 A SV2003000600 A SV 2003000600A
- Authority
- SV
- El Salvador
- Prior art keywords
- therapeutic combination
- ref
- combinations
- combination ref
- hydroxylic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 abstract 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 230000000747 cardiac effect Effects 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMBINACIONES FARMACEUTICAS DE UN INHIBIDOR DE CETP Y ATORVASTATINA O SUS METABOLITOS HIDROXILICOS O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, METODOS PARA UTILIZAR TALES COMBINACIONES Y KITS QUE CONTIENEN TALES COMBINACIONES PARA EL TRATAMIENTO DE ATEROSCLEROSIS, ANGINA DE PECHO, NIVELES ELEVADOS DE COLESTEROL Y NIVELES BAJOS DE HDL Y PARA EL TRATAMIENTO DEL RIESGO CARDIACO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22523800P | 2000-08-15 | 2000-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2003000600A true SV2003000600A (es) | 2003-01-13 |
Family
ID=22844100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2001000600A SV2003000600A (es) | 2000-08-15 | 2001-08-14 | Combinacion terapeutica ref. pc11025aado/bb |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20020035125A1 (es) |
| EP (1) | EP1309329A2 (es) |
| JP (1) | JP2004506008A (es) |
| KR (1) | KR20030069983A (es) |
| CN (1) | CN1735416A (es) |
| AP (1) | AP2003002743A0 (es) |
| AU (1) | AU2001270937A1 (es) |
| BG (1) | BG107515A (es) |
| BR (1) | BR0113200A (es) |
| CA (1) | CA2419406A1 (es) |
| CZ (1) | CZ2003390A3 (es) |
| DZ (1) | DZ3409A1 (es) |
| EA (1) | EA200300155A1 (es) |
| EC (1) | ECSP034478A (es) |
| HR (1) | HRP20030104A2 (es) |
| HU (1) | HUP0303083A3 (es) |
| IL (1) | IL154348A0 (es) |
| IS (1) | IS6700A (es) |
| MX (1) | MXPA03001419A (es) |
| NO (1) | NO20030725D0 (es) |
| PA (1) | PA8525301A1 (es) |
| PE (1) | PE20020340A1 (es) |
| SK (1) | SK1742003A3 (es) |
| SV (1) | SV2003000600A (es) |
| TN (1) | TNSN01125A1 (es) |
| UY (1) | UY26883A1 (es) |
| WO (1) | WO2002013797A2 (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044459A1 (en) * | 2001-09-04 | 2003-03-06 | Pfizer Inc. | Biomodulated multiparticulate formulations |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| ATE461700T1 (de) | 2002-12-20 | 2010-04-15 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
| EP1581210B1 (en) * | 2002-12-20 | 2008-03-19 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| CA2526730A1 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives |
| WO2005011634A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| CN101342162A (zh) | 2003-09-26 | 2009-01-14 | 日本烟草产业株式会社 | 抑制残余脂蛋白产生的方法 |
| CN1942428A (zh) * | 2004-04-13 | 2007-04-04 | 默克公司 | Cetp抑制剂 |
| EP1845953A1 (en) * | 2005-02-03 | 2007-10-24 | Pfizer Products Incorporated | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| NZ594395A (en) | 2009-02-10 | 2014-01-31 | Amarin Pharmaceuticals Ie Ltd | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
| US20120100208A1 (en) | 2009-04-29 | 2012-04-26 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
| US20120093922A1 (en) | 2009-04-29 | 2012-04-19 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| SG177254A1 (en) | 2009-06-15 | 2012-02-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| WO2012074930A2 (en) | 2010-11-29 | 2012-06-07 | Amarin Pharma, Inc. | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| PT4342546T (pt) | 2012-06-29 | 2025-09-01 | Amarin Pharmaceuticals Ie Ltd | Éster etílico do ácido eicosapentanoico para utilização na redução do risco de acidente vascular cerebral não-fatal num indivíduo em terapia com estatina |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| DK4056176T3 (da) | 2018-09-24 | 2024-05-06 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåde til at reducere risikoen af kardiovaskulære hændelser hos et individ |
| US12427134B2 (en) | 2019-11-12 | 2025-09-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| US6462091B1 (en) * | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
-
2001
- 2001-07-23 KR KR10-2003-7002220A patent/KR20030069983A/ko not_active Withdrawn
- 2001-07-23 HR HR20030104A patent/HRP20030104A2/hr not_active Application Discontinuation
- 2001-07-23 JP JP2002518943A patent/JP2004506008A/ja not_active Withdrawn
- 2001-07-23 CA CA002419406A patent/CA2419406A1/en not_active Abandoned
- 2001-07-23 SK SK174-2003A patent/SK1742003A3/sk not_active Application Discontinuation
- 2001-07-23 HU HU0303083A patent/HUP0303083A3/hu unknown
- 2001-07-23 MX MXPA03001419A patent/MXPA03001419A/es not_active Application Discontinuation
- 2001-07-23 EP EP01949825A patent/EP1309329A2/en not_active Ceased
- 2001-07-23 CZ CZ2003390A patent/CZ2003390A3/cs unknown
- 2001-07-23 WO PCT/IB2001/001309 patent/WO2002013797A2/en not_active Ceased
- 2001-07-23 AU AU2001270937A patent/AU2001270937A1/en not_active Abandoned
- 2001-07-23 AP APAP/P/2003/002743A patent/AP2003002743A0/en unknown
- 2001-07-23 BR BR0113200-8A patent/BR0113200A/pt not_active IP Right Cessation
- 2001-07-23 EA EA200300155A patent/EA200300155A1/ru unknown
- 2001-07-23 CN CNA018150667A patent/CN1735416A/zh active Pending
- 2001-07-23 DZ DZ013409A patent/DZ3409A1/fr active
- 2001-07-23 IL IL15434801A patent/IL154348A0/xx unknown
- 2001-08-14 PE PE2001000810A patent/PE20020340A1/es not_active Application Discontinuation
- 2001-08-14 US US09/929,862 patent/US20020035125A1/en not_active Abandoned
- 2001-08-14 UY UY26883A patent/UY26883A1/es not_active Application Discontinuation
- 2001-08-14 TN TNTNSN01125A patent/TNSN01125A1/fr unknown
- 2001-08-14 SV SV2001000600A patent/SV2003000600A/es not_active Application Discontinuation
- 2001-08-14 PA PA20018525301A patent/PA8525301A1/es unknown
-
2003
- 2003-01-27 IS IS6700A patent/IS6700A/is unknown
- 2003-02-03 BG BG107515A patent/BG107515A/xx unknown
- 2003-02-13 EC EC2003004478A patent/ECSP034478A/es unknown
- 2003-02-14 NO NO20030725A patent/NO20030725D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0303083A3 (en) | 2005-05-30 |
| HUP0303083A2 (hu) | 2003-12-29 |
| PA8525301A1 (es) | 2002-04-25 |
| EA200300155A1 (ru) | 2003-08-28 |
| WO2002013797A3 (en) | 2003-03-13 |
| IL154348A0 (en) | 2003-09-17 |
| DZ3409A1 (fr) | 2002-02-21 |
| WO2002013797A2 (en) | 2002-02-21 |
| BG107515A (en) | 2003-09-30 |
| US20020035125A1 (en) | 2002-03-21 |
| CN1735416A (zh) | 2006-02-15 |
| JP2004506008A (ja) | 2004-02-26 |
| TNSN01125A1 (fr) | 2005-11-10 |
| ECSP034478A (es) | 2003-03-31 |
| EP1309329A2 (en) | 2003-05-14 |
| NO20030725D0 (no) | 2003-02-14 |
| AU2001270937A1 (en) | 2002-02-25 |
| IS6700A (is) | 2003-01-27 |
| MXPA03001419A (es) | 2003-06-06 |
| HRP20030104A2 (en) | 2003-04-30 |
| CA2419406A1 (en) | 2002-02-21 |
| UY26883A1 (es) | 2002-03-22 |
| CZ2003390A3 (en) | 2004-03-17 |
| BR0113200A (pt) | 2003-09-16 |
| SK1742003A3 (en) | 2004-06-08 |
| PE20020340A1 (es) | 2002-05-10 |
| KR20030069983A (ko) | 2003-08-27 |
| AP2003002743A0 (en) | 2003-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2003000600A (es) | Combinacion terapeutica ref. pc11025aado/bb | |
| DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
| UY30460A1 (es) | Compuestos terapéuticos | |
| DK1589956T3 (da) | Transdermal granisetron | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| ECSP088296A (es) | Compuestos terapéuticos | |
| GT200300053A (es) | Compuestos que modulan la actividad de ppar | |
| GT200300054A (es) | Compuestos que modulan la actividad de ppar | |
| UY27740A1 (es) | Nuevos compuestos | |
| PA8518801A1 (es) | Derivados de 2-aminocarbonil-9h-purina | |
| AR017514A1 (es) | Composicion farmaceutica, una primera composicion para usarse como una segunda composicion, un estuche, procedimiento para tratar un mamifero | |
| GT200500098A (es) | Nuevos compuestos | |
| BR112022026186A2 (pt) | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| MX2022006176A (es) | Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2. | |
| DE60127537D1 (de) | VERWENDUNG VON 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLOÄ1,5-bÜPYRIDAZINE ZUR BEHANDLUNG VON NICHTULZERATIVER DYSPEPSIE | |
| PA8529701A1 (es) | Compuestos retinoides | |
| CL2011002233A1 (es) | Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico. | |
| CL2015001086A1 (es) | Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas | |
| WO2003094367A3 (en) | Improved first aid kit instructions | |
| NO20023111L (no) | Utvortes preparat for behandling av pruritus | |
| GT200600516A (es) | Derivados de piperidina | |
| MXPA02012029A (es) | Kit para reducir dolor continuo. | |
| BRPI0507859A (pt) | uso dos inibidores da colinesterase | |
| GT199900083A (es) | Combinaciones terapeuticas para la fragilidad musculoesqueletica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |